Cholesterol-lowering statins significantly lower the increased concentrations of coagulation and inflammation markers, both cardiovascular disease risk factors common in type 2 diabetes.
According to a randomized 50-patient study in the Netherlands, after eight weeks of treatment with pravastatin (marketed in the United States as Pravachol), researchers observed significant reductions in three plasma coagulation and inflammation markers, as well as a 13 percent reduction in C-reactive protein, an indicator of inflammation.
The researchers speculate that the anti-thrombotic and anti-inflammatory effects of statin treatment could play a role in reducing the cardiovascular complications associated with type 2 diabetes.
-Diabetes Care, February 2004
Clinical adviser’s note: For more information on the class of lipid-regulating drugs called HMG-CoA reductase inhibitors (“statins” for short), please refer to our January 2004 Product Reference Guide issue, pp. 38-44.